We’re excited about the products we have in the pipeline and the impact they will have on patients.

Product Indication Preclin Phase One Phase Two Phase Three
KIO-301 (Intravitreal) Retinitis Pigmentosa
KIO-101 (Eyedrop) Ocular Manifestations of Rheumatoid Arthritis
KIO-201 (Eyedrop) Persistent Corneal Epithelial Defects
KIO-201 (Eyedrop) Corneal Surgical Wounds
KIO-301 received Orphan Drug Designation from the FDA on March 17, 2022.
These therapeutics are still in development and are not yet approved for commercial use.
Loading RSS Feed